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(MC1R–MC5R). Of these, MC2R and
MC5R have been proposed to act
directly in adipocytes and to regulate
lipolysis in rodents (Mller et al., 2011).
a-MSH-stimulated lipolysis is mediated
through MC5R in a cAMP-independent
manner. This suggests that more cAMP-
independent functions can be anticipa-
ted for MC1R, but a role for MC1R in
adipocytes (and, thereby, influencing
birth weight) has not yet been shown.
The findings by Kinsler et al. (2012)
expand the known phenotypical varia-
tions associated with polymorphisms in
the MC1R gene.
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Toll-Like Receptors in Wound Healing:
Location, Accessibility, and Timing
Mohan R. Dasu1 and R. Rivkah Isseroff1
Toll-like receptors (TLRs) are considered to be the first responders in the defense
against invading pathogens. TLR engagement by ligands triggers inflammatory
responses in injury and trauma, and thus can impair or contribute to the healing
process, depending on TLRs’ expression pattern, cellular localization, signaling,
and deployment of inflammatory responses. Understanding these attributes could
improve therapeutic strategies for treating chronic wounds.
Journal of Investigative Dermatology (2012) 132, 1955–1958. doi:10.1038/jid.2012.208
Toll-like receptor (TLR) activation and
signaling
The interaction of multiple cell types—
and their activation in the inflammatory,
proliferative, and remodeling phases of
cutaneous wound healing—is orche-
strated by the temporo-spatially con-
strained expression of a host of cyto-
kines and growth factors. Lin et al. 2012,
this issue highlight yet another class of
mediators, contributing a new melody
to the expanding symphony of wound
healing modulation: TLR, activators of
the innate immunity. Although the cur-
rent report focuses on the role of TLR3, it
is worthwhile to examine the complex
interactions of TLRs in wound repair.
TLRs present on immune cells such as
macrophages, neutrophils, and dendritic
cells recognize bacterial and fungal com-
ponents (cell surface: TLRs1–6), whereas
intracellular TLRs recognize viral double-
stranded RNA (TLR3), viral single-stran-
ded RNA (TLR7 and TLR8), and micro-
bial DNA (TLR9) (Kenny and O’Neill,
2008). In addition, TLRs can interact with
endogenous ligands produced by stres-
sed, injured, or damaged cells, such as
heat shock proteins 60 and 70, fibrino-
gen, and fibronectin (Mollen et al.,
2006). Thus, TLRs provide a system for
an immunomodulatory response to a host
of potential pathogens or endogenous
signals of cell stress.
When a TLR ligand binds to its
receptor, one of two events takes place:
either a receptor dimer is formed or the
conformation of a pre-existing dimer
changes in such a way that it brings
two intracellular Toll-IL-1 receptor
(TIR) domains of the TLRs to interact
physically. This simple rearrangement
facilitates the nucleating act for the
recruitment of downstream signaling
adaptor proteins (Manavalan et al.,
2011). Signaling cascades via the intra-
cellular TIR domains are mediated by
specific adaptor molecules such as
MyD88 (myeloid differentiation factor 88),
Mal (MyD88 adaptor-like), TRIF (TIR
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domain–containing adaptor inducing
IFN-b), and TRAM (TRIF-related adaptor
molecule) (Kenny and O’Neill, 2008).
These adaptor proteins also contain TIR
domains that mediate TIR–TIR inter-
actions between TLR receptors,
receptor–adaptor, and adaptor–adaptor
interactions that are critical for signal-
ing. MyD88 is the most common adap-
tor molecule involved in most TLR
signaling, with the exception of TLR3,
which uses TRIF/TRAM to activate the
IFN pathway. TLR4 has been shown to
use all four described TIR-containing
adaptors; MyD88 and Mal (also known
as TIRAP) seem to act in tandem to
activate the MyD88-dependent path-
way, resulting in NF-kB activation
(Trinchieri and Sher, 2007; Kenny
and O’Neill, 2008). Two impor-
tant conclusions can be gleaned from
examining these signaling pathways: first,
the disparate wound healing outcomes
of activation of a given TLR appear to
be a function of the distinct downstream
signaling components recruited post
activation, and, second, these adaptors
are then amenable to specific targeting
mechanisms to disrupt their signaling,
and impact upon the downstream out-
comes (Trinchieri and Sher, 2007; Dunne
et al., 2011) (Figure 1).
How TLRs impact wound healing
There is compelling experimental
evidence that engagement of the TLRs
by endogenous ligands triggers inflam-
matory responses to ischemia, hemor-
rhagic shock, ischemia/reperfusion,
burn injuries, and full-thickness exci-
sional wounding (Mollen et al., 2006),
and thus could either impair or enhance
the healing process, depending on how
and when the inflammatory responses
were deployed. For example, we
recently showed that wounds created
in diabetic, healing-impaired mice in
which TLR2 has been genetically
deleted heal more rapidly than wounds
in wild-type, TLR2-expressing animals,
and the improved healing correlates
with decreased wound inflammation
(Dasu et al., 2010), suggesting that sus-
tained TLR2 expression/activation may
be detrimental to diabetic wounds. On
the other hand, similar to the experi-
mental paradigm employed here by Lin
et al. 2012, where activation of TLR3 by
application of its agonist polyinosinic:
polycytidylic acid (poly I:C) improves
healing, Deiters et al. 2004 found that
the activation of TLR2 by topical appli-
cation of its agonist, macrophage-
activating lipopeptide-2, resulted in
accelerated healing in diabetic murine
skin wounds. Timing of the application
of the TLR ligand (early in the healing
cascade) may be a critical element in
determining whether the TLR-induced
inflammation impairs or improves heal-
ing. Yet another element may be the
accessibility of the ligand to cells bear-
ing the cognate receptor. When the
TLR3 ligand poly I:C was administered
to guinea pigs subcutaneously or intra-
muscularly, it failed to induce a signi-
ficant inflammatory response (either
local tumor necrosis factor-a and IL-6
secretion or systemic fever) even at high
doses, whereas much lower intra-
arterially administered doses induced
robust inflammatory responses, sugges-
ting that the route of presentation of the
TLR agonist and its access to cells
bearing the receptor dictate the nature
of the response (Voss et al., 2006). Lin
et al. 2012 show that topical application
of the TLR3 ligand poly I:C to a wound
provides sufficient access to TLR3-
bearing cells to activate its signaling
cascade, recruit neutrophils and macro-
phages to the wound, and accelerate
healing, thus demonstrating a potential
topical therapeutic approach for enhan-
cing wound repair. Similarly, spatial
localization of TLR4 ligands may also
modify the nature of the healing res-
ponse. Although increased TLR4 expres-
sion and activation contributes to adverse
wound healing outcomes via microvas-
cular dysfunction during non-septic
thermal injury (Breslin et al., 2008), the
exposure of epithelial cells to the TLR4
agonist, Pseudomonas lipopolysaccha-
ride, improves epithelial wound healing
(Koff et al., 2006). Thus, the activation of
TLR4 in the dermis, as opposed to the
epidermis, may result in different out-
comes.
TLR2, TLR3, and TLR4 are present in
normal human skin—in keratinocytes,
fibroblasts, and Langerhans cells, resi-
dent and trafficking immune cells, such
as macrophages, dendritic cells, T and B
cells, and mast cells in the dermis, as
well as endothelial cells of the skin
microvasculature (Miller and Modlin,
2007). By contrast, TLR9 messenger
RNA expression increases only after epi-
dermal damage or microbial infection,
suggesting that this TLR9 derives from
infiltrating peripheral blood mono-
nuclear cells from peripheral blood
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Figure 1. Toll-like receptor (TLR) signaling and its role in skin wound healing. All TLRs are
transmembrane proteins with leucine-rich repeats in the extracellular domain and a unique Toll-IL-1
receptor (TIR) domain. All TLR family members except TLR3 signal through myeloid differentiation factor
88 (MyD88). For TLR2 and TLR4, MyD88 adaptor-like protein (Mal) protein is required for recruiting
MyD88 to their receptors, whereas Mal is not required for TLR3, 7, 8, and 9. TLR3 signals through the
adaptor TIR domain–containing adaptor protein inducing IFN-b-mediated transcription factor (TRIF) in a
non-Mal/MyD88-dependent pathway. IRF3, interferon regulatory factor 3; TRAF6, tumor necrosis factor
receptor–associated factor 6.
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(Liu et al., 2003). TLR activation in fibro-
blasts may contribute to the dermal
component of wound healing, as has
been suggested by findings of increased
TLR4 expression in fibroblasts isolated
from hypertrophic scars, and conco-
mitant upregulation of MyD88 expres-
sion, prostaglandin E2, IL-6, IL-8, and
monocyte chemotactic protein-1 com-
pared with normal skin tissue (Wang
et al., 2011). Novel TLR regulatory
networks in the skin continue to be
discovered, including a recent finding
by Schauber et al., 2007 that cutaneous
injury upregulates vitamin D3 genera-
tion in keratinocytes, which then increa-
ses keratinocyte TLR2 expression.
Following skin injury, an early and short-
lived infiltration of plasmacytoid den-
dritic cells (pDC) occurs in the wounds.
These pDCs produce IFN-a/b through
TLR7 and TLR9, suggesting that they
recognize self-nucleic acids released by
damaged cells in skin wounds (Gregorio
et al., 2011). Thus, TLR expression and
activation (resulting in increased pro-
inflammatory cytokine generation) have
diverse roles in wound healing and are
dependent upon the cell type in which
they are activated and the subset of cell
types recruited to the wound.
It is interesting to note an emerging
theme with respect to the potential role
of cell surface (TLR2/4) as opposed to
intracellular TLRs (TLR3/9) in wound
healing. It appears that increased exp-
ression of cell surface receptors (TLR2/4)
in wounds contributes to a prolonged
inflammatory phase and impaired heal-
ing (Breslin et al., 2008; Dasu et al.,
2010). On the other hand, the absence
of intracellular TLR3 or TLR9 worsens
healing, and the activation of these TLRs
using poly I:C either to activate TLR3
(Lin et al., 2012) or TLR9 by its agonist
(Sato et al., 2010) enhances healing.
In addition, macrophages can be modu-
lated by TLR activation: TLR2/4 activa-
tion results in a proinflammatory M1
phenotype, whereas TLR3 activation, at
least through poly I:C, induces the anti-
inflammatory M2 phenotype (Lin et al.,
2012). These new studies will surely
prompt continued investigation into the
intricacies of the temporo-spatial regula-
tion of TLR expression and activation in
skin wounds, the role of the skin biome
in normal and wounded skin on TLR
signaling, the identity of endogenous
TLR ligands, and how their localization
and timing of expression impact this
process.
Acute versus chronic wounds
Although innate immune responses via
TLRs in acute skin wounds have been
well studied (Deiters et al., 2004;
Schauber et al., 2007; Breslin et al.,
2008; Dasu et al., 2010; Wang et al.,
2011), there is limited information
available regarding TLR expression and
roles in chronic wounds. Chronic skin
wounds are a major global health problem
and a considerable economic burden. The
cost of care for diabetic patients with foot
ulcers is 5.4 times higher in the first year of
the ulcer episode and 2.8 times higher in
the second year compared with diabetic
patients without foot ulcers (Driver et al.,
2010). Although the precise mole-
cular pathogenesis of chronic wounds is
unclear, some associations are known: a
sustained inflammatory response and the
frequent bacterial colonization of the
wound bed, two interrelated factors, are
believed to contribute to wound chroni-
city (Acosta et al., 2008). In a recent study,
Pukstad et al. 2010 demonstrated that
non-healing venous leg ulcers were asso-
ciated with persistent activation of TLR2/4
and cytokine expression (elevated levels of
IL1-b, IL-8, and MIP1a), whereas decrea-
sed levels were associated with healing.
Nevertheless, no studies are available as
yet to elucidate the role of TLRs in human
diabetic wounds, either infected or non-
infected. These studies are sorely needed,
as they have the potential to guide the
development of novel small-molecule
inhibitors targeting TLRs or their ligands,
exogenous and endogenous, as wound
therapeutics (Dunne et al., 2011).
The future of TLRs in wound healing
Mounting evidence suggests that TLRs
have important roles in wound healing.
All TLRs modulate the innate immune
response; however, they differ in their
temporo-spatial expression pattern, cel-
lular localization, signaling pathways,
and physiological outcomes (wound
healing). TLR-dependent signaling and
inflammation in chronic wounds
remains understudied. For example, it
is not yet known whether cells other
than macrophages, such as the wound-
resident keratinocytes and fibroblasts
that express TLRs, can also recognize
DNA viruses, bacteria, and damaged
host cells in acute and chronic wounds
and thus contribute to the healing. It will
be important to identify the sensors,
cellular effectors, and downstream
signaling pathways by which TLRs
impact healing and induce innate
immune responses. Such knowledge
will improve therapeutic strategies for
treating chronic wounds.
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